|Day Low/High||34.50 / 38.44|
|52 Wk Low/High||35.70 / 56.10|
We are effectively swapping out shares of Allergan, Apache and GE for more Amazon.
We'll sell shares of Allergan, Apache and GE, which have trended lower for a year. Plus, an announcement on our annual donation to charity!
As quick as last week's selloff occurred, this rebound higher has been just as fast, and we would not be surprised to see the market retest at some point.
The recent lows have taken out a previously positive chart formation.
I'm not optimistic about Trump's infrastructure plan, but defense stocks, Halliburton and Schlumberger are another story.
Jim discusses our First Data Corp exit, his interview with Broadcom's CEO, Nvidia, and his Real Money article from earlier today.
Some of the recent money that just piled into equities in January has already headed for the exits.
Maybe inverse and/or leveraged positions are perverse in nature.
It's February already. These stocks are ones that you should check out quickly.
Jim discusses Honeywell and Abbott Labs earnings as well as Broadcom and the oils.
Natural gas is currently popping, and Apache stands to benefit from this.
Currency traders see the Trump administration boosting manufacturing via a weak dollar.
If you followed our advice you should be long APA.
APA made a very impressive stand and now looks ready for a break higher.
Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APA, DISCB, NBL Downgrades: LOB, PANL, WAT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.
Over-extension? Yeah, that could be it, or maybe the inflows of cash are merely slowing down.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.